

4.0.3 DOC Cmte minutes

Dementia Guideline Committee meeting 15 – development

Date: 25/05/2017

Location: NICE offices, London

Minutes: Final



Committee members present:	
Damien Longson (DL) (chair)	Present for all
Louise Allan (LA)	Present from item 2
Linda Clare (LC)	Present until partway through item 6
Carol Duff (CD)	Present for all
Kim Grosvenor (KM)	Present for all
Sandra Evans (SE)	Present for all
Karen Harrison-Denning (KHD)	Present for all
Jeremy Isaacs (JI)	Present for all
Kevin Minier (KMin)	Present for all
Hannah Luff (HL)	Present for all
Sarah Partington (SP)	Present for all
Louise Robinson (LR)	Present for all
Chris Roberts (CR)	Present for all
John O'Brien (JO)	Present for all

In attendance:		
Sohaib Ashraf (SA)	NICE – Health Economist	Present from item 2
Vicky Gillis (VG)	NICE – Technical Analyst	Present for all
Justine Karpusheff (JK)	NICE – Guideline commissioning manager	Present for items: 1, 2, 5, 6, & 7
Toby Mercer (TM)	NICE – Technical Analyst	Present from partway through item 5
Vonda Murray (VM)	NICE – Project Manager	Present for all
Angela Parkin (AP)	NICE – Medicines Advisor	Present for all
Joshua Pink (JP)	NICE – Technical Advisor	Present for all
Gabriel Rogers (GR)	NICE – Health Economic Advisor	Present for all

4.0.3 DOC Cmte minutes

Apologies:	
Elizabeth Barrett (EB)	NICE – Information Specialist
Joanne Brady (JB)	Co-opted committee member
Richard Clibbens (RC)	Committee member
Wayne Goddard (WG)	Committee member
Ruth O’Dea (RO)	Committee member
Sue Spiers (SS)	NICE – Associate Director
Tracey Wright (TW)	Committee member
Kate Mitchell (KM)	Co-opted member

Item 1 - Welcome, apologies, objectives for the meeting, declaration of interests and minutes of previous meeting

The Chair welcomed the committee members and attendees to the fifteenth meeting of the dementia guideline committee. The committee members introduced themselves. JK and KG were welcomed to the committee.

Apologies were noted, as recorded above, and minutes of the last meeting were agreed as an accurate record of the meeting.

All Committee members were asked to share any new conflicts of interest which have not previously been declared.

Kim Grosvenor	Prime Minister’s Rural Dementia Task and Finish Group contributor and in particular, the recommendations associated with the PM’s Charter.
---------------	--

The Chair reviewed historical declaration of interests it was agreed that all committee members were eligible to attend the committee meeting and contribute to the discussions and drafting of any recommendations.

The Chair outlined the proposed objectives of the meeting.

Item 2 - RQ2 - When should treatment with donepezil, galantamine, rivastigmine, memantine be withdrawn for people with Alzheimer’s disease?

- Presentation of clinical evidence
- Agree evidence statements

JP presented the clinical evidence that was found for when donepezil, galantamine, rivastigmine, memantine treatment should be withdrawn for people with Alzheimer’s disease. GR provided an overview to the committee of the health economic evidence that was found. The committee discussed the evidence presented and agreed the evidence statements. The committee agreed at this stage that they could make recommendations, 2 recommendations were made.

4.0.3 DOC Cmte minutes

Item 3 - RQ33: How effective is the co-prescription of anticholinesterase inhibitors and memantine for the treatment of Alzheimer's disease?

- Presentation of clinical evidence
- Agree evidence statements

VG recapped the review protocol reminding the committee of the agreed inclusion criteria. VG presented the evidence for the effectiveness of co-prescribing of anticholinesterase inhibitors and memantine for the treatment of Alzheimer's disease. Following the presentation the committee discussed the evidence and agreed the evidence statements. The committee made 3 recommendations.

Item 4 - RQ2 - When should treatment with donepezil, galantamine, rivastigmine, memantine be withdrawn for people with Alzheimer's disease?**RQ33 - How effective is the co-prescription of anticholinesterase inhibitors and memantine for the treatment of Alzheimer's disease?**

- Recommendations

Recommendations for the review questions RQ2 and RQ33, were made after the presentation of the evidence for each question.

Item 5 - Health Economics model

SA reminded the committee which questions health economic modelling was concentrating on, and provided an update on the work that had been carried out to date on the model. Furthermore, SA provided the committee with an insight into the types of assumptions that will go into the de novo economic analysis, and an opportunity to shape them. The committee asked questions, and provided input into the modelling for the guideline.

Item 5 - RQ12: What effect does training for staff working with people living with dementia have upon the experiences of people living with dementia in their care?

- Update from sub group

TM provided an overview of the evidence that was presented to the social care sub-group on the effect training for staff working with people living with dementia have upon the experiences of people living with dementia in their care. The committee discussed the recommendations that were made by the sub group, the committee agreed changes to these recommendations. The committee made 2 further recommendations.

5. AOB & Close

VM provided a summary of next steps

JP provided an update on the topics for discussion at the next meeting.

The committee agreed an amended start and finish time for the next committee meeting

Monday 10th July - 10:30 to 17:00

Tuesday 11th July - 09:00 to 16:00

4.0.3 DOC Cmte minutes

NICE offices, Manchester